Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, Feng H, Girgis S, Cakana A, van de Velde H, Deraedt W, Facon T. Moreau P, et al. Among authors: cakana a. Clin Pharmacokinet. 2012 Dec;51(12):823-9. doi: 10.1007/s40262-012-0010-0. Clin Pharmacokinet. 2012. PMID: 23018466 Clinical Trial.
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Arnulf B, et al. Among authors: cakana a. Haematologica. 2012 Dec;97(12):1925-8. doi: 10.3324/haematol.2012.067793. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689676 Free PMC article. Clinical Trial.
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P. Sonneveld P, et al. Among authors: cakana a. J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897961
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Harousseau JL, et al. Among authors: cakana a. Blood. 2010 Nov 11;116(19):3743-50. doi: 10.1182/blood-2010-03-275800. Epub 2010 Jul 13. Blood. 2010. PMID: 20628153 Free article. Clinical Trial.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF. Dimopoulos MA, et al. Among authors: cakana a. Eur J Haematol. 2011 Jan;86(1):23-31. doi: 10.1111/j.1600-0609.2010.01533.x. Epub 2010 Nov 15. Eur J Haematol. 2011. PMID: 20874823 Clinical Trial.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimopoulos MA, Kropff M, Spicka I, Petrucci MT, Samoilova OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF. Delforge M, et al. Among authors: cakana a. Eur J Haematol. 2011 May;86(5):372-84. doi: 10.1111/j.1600-0609.2011.01599.x. Epub 2011 Mar 30. Eur J Haematol. 2011. PMID: 21366694 Clinical Trial.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Richardson P, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Richardson P, et al. Among authors: cakana a. Br J Haematol. 2011 Apr;153(2):212-21. doi: 10.1111/j.1365-2141.2011.08569.x. Epub 2011 Mar 6. Br J Haematol. 2011. PMID: 21375521 Free article. Clinical Trial.
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, Cakana A, van de Velde H, Richardson PG, San Miguel JF. Delforge M, et al. Among authors: cakana a. Eur J Haematol. 2012 Jul;89(1):16-27. doi: 10.1111/j.1600-0609.2012.01788.x. Epub 2012 May 7. Eur J Haematol. 2012. PMID: 22469559 Clinical Trial.
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. San Miguel JF, et al. Among authors: cakana a. J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233713 Free article. Clinical Trial.
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA, van de Velde H, Schaffer ME, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Romejko-Jarosinska J, de Vos S, Crump M, Shpilberg O, Zinzani PL, Cakana A, Esseltine DL, Mulligan G, Ricci D. Coiffier B, et al. Among authors: cakana a. Clin Cancer Res. 2013 May 1;19(9):2551-61. doi: 10.1158/1078-0432.CCR-12-3069. Epub 2013 Apr 2. Clin Cancer Res. 2013. PMID: 23549871
31 results